- Conditions
- Colorectal Cancer
- Interventions
- FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 943
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Neoplasm Metastasis
- Interventions
- Bevacizumab, Pemetrexed, Vitamin B12, Folate, Dexamethasone
- Drug
- Lead sponsor
- Heather Wakelee
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 4
- States / cities
- Stanford, California • Lebanon, New Hampshire • Voorhees Township, New Jersey + 1 more
- Conditions
- Gastric Cancer
- Interventions
- Placebo, Onartuzumab (MetMAb), Oxaliplatin, Folinic acid, Levofolinic acid, 5-Fluorouracil
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 18
- States / cities
- Denver, Colorado • New Haven, Connecticut • Fort Myers, Florida + 15 more
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer
- Interventions
- oxaliplatin, leucovorin calcium, fluorouracil, placebo, vismodegib, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 30
- States / cities
- Sacramento, California • Chicago, Illinois • Decatur, Illinois + 16 more
- Conditions
- Colorectal Cancer
- Interventions
- Pembrolizumab, mFOLFOX6
- Drug
- Lead sponsor
- Hoosier Cancer Research Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Indianapolis, Indiana • Columbus, Ohio
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Fluorouracil, Irinotecan, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Pegcetacoplan
- Procedure · Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Biliary Tract Cancer
- Interventions
- "Bevacizumab" in combination with "modified FOLFOX6".
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Metastatic Pancreas Adenocarcinoma
- Interventions
- 5FU, nab-paclitaxel, bevacizumab, calcium leucovorin, oxaliplatin
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 4 more
- Conditions
- Neoplasms
- Interventions
- gemcitabine, fluorodeoxyuridine, leucovorin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Stage IB Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IIIC Esophageal Adenocarcinoma
- Interventions
- Paclitaxel, Carboplatin, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Radiation Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis
- Drug · Radiation · Procedure + 1 more
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Stage IV Colon Cancer, Stage IV Rectal Cancer
- Interventions
- leucovorin calcium, bevacizumab, cholecalciferol, fluorouracil, oxaliplatin, pharmacological study
- Drug · Biological · Dietary Supplement + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- Folfirinox alternating with Gemcitabine-nab-Paclitaxel
- Drug
- Lead sponsor
- Lyudmyla Berim
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 7
- States / cities
- Hamilton, New Jersey • Jersey City, New Jersey • Livingston, New Jersey + 4 more
- Conditions
- Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Colon, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Interventions
- cetuximab, bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Trimethoprim, Sulfamethoxazole, Leucovorin calcium
- Drug
- Lead sponsor
- Lederle Laboratories
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Pancreatic Cancer
- Interventions
- Biopsy, FOLFIRINOX, Ciprofloxacin, Metronidazole, Pembrolizumab, Surgical Resection
- Procedure · Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Gastrointestinal Cancer
- Interventions
- Oxaliplatin, Capecitabine, Leucovorin, 5-fluorouracil, radiation
- Drug · Radiation
- Lead sponsor
- Tannaz Armaghany
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- Houston, Texas
- Conditions
- Solid Tumors
- Interventions
- Ramucirumab (IMC-1121B), Irinotecan, Folinic acid, 5-Fluorouracil
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 5
- States / cities
- Detroit, Michigan • Las Vegas, Nevada • Cleveland, Ohio + 2 more
- Conditions
- Solid Tumors
- Interventions
- triacetyluridine, fluorouracil, leucovorin, camptosar
- Drug
- Lead sponsor
- Wellstat Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Gastric Cardia, Stage IIIA Esophageal Cancer, Stage IIIB Esophageal Cancer, Stage IIIC Esophageal Cancer
- Interventions
- oxaliplatin, leucovorin calcium, fluorouracil, therapeutic conventional surgery, radiation therapy, carboplatin, paclitaxel
- Drug · Procedure · Radiation
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
- Interventions
- AZD9592, Osimertinib, 5-Fluorouracil (5-FU), Leucovorin, Bevacizumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 15
- States / cities
- Duarte, California • North Haven, Connecticut • Washington D.C., District of Columbia + 9 more
- Conditions
- Gastric Cancer, Peritoneal Carcinomatosis, Gastroesophageal Junction Adenocarcinoma
- Interventions
- Paclitaxel, Leucovorin, Fluorouracil
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Rectal Cancer
- Interventions
- FOLFOXIRI, FOLFOX regimen, XELOX, IMRT
- Drug · Radiation
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Neoplasms
- Interventions
- GSK5764227, Bevacizumab, Fluorouracil, leucovorin, Enzalutamide
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 5
- States / cities
- Reunion, Florida • New Hyde Park, New York • Philadelphia, Pennsylvania + 2 more
- Conditions
- Esophageal Cancer
- Interventions
- Docetaxel, Floxuridine, Leucovorin, Oxaliplatin, Microarray analysis, reverse transcriptase-polymerase chain reaction, Conventional surgery
- Drug · Genetic · Procedure
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Miami, Florida